AGPI 2
Alternative Names: AGPI-2Latest Information Update: 06 Jun 2024
At a glance
- Originator Agyany Pharmaceuticals
- Class Antiparkinsonians
- Mechanism of Action Glucosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 23 May 2024 Preclinical trials in Parkinson's disease in Israel (unspecified route) prior to May 2024 (Agyany Pharmaceuticals pipeline, May 2024)